Discovery could broaden effectiveness of emerging therapies for cancer and other diseases that are based on boosting the natural immune system response
Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to maximize the effectiveness of anti-cancer immune therapy. The researchers identified a molecular switch that controls immune suppression, opening the possibility to further improving and refining emerging immunotherapies that boost the body’s own abilities to fight diseases ranging from cancer to Alzheimer’s and Crohn’s disease.
The findings are published in the September 19 online issue of Nature.
“Immunotherapies, such as T cell checkpoint inhibitors, are showing great promise in early treatments and trials, but they are not universally effective,” said Judith A. Varner, PhD, professor in the Departments of Pathology and Medicine at UC San Diego School of Medicine. “We have identified a new method to boost the effectiveness of current immune therapy. Our findings also improve our understanding of key mechanisms that control cancer immune suppression and could lead to the development of more effective immunotherapies.”
When confronted by pathogens, injury or disease, the initial response of the body’s immune system comes in the form of macrophages, a type of white blood cell that express pro-inflammatory proteins called cytokines that, in turn, activate T cells, another immune cell, to attack the health threat. The macrophages then switch gears to express other cytokines that dampen T cell activation, stimulating tissue repair.
In chronic inflammatory diseases such as Alzheimer’s and Crohn’s, however, macrophages associated with the malignancy continue to produce pro-inflammatory cytokines and other substances that kill or transform normal cells. In cancer, highly abundant microphages express anti-inflammatory cytokines that induce immune suppression, effectively stopping the healing process.
In the Nature paper, Varner and colleagues pinpoint a key, suspected player: an enzyme in macrophages called PI-3 kinase gamma (PI3Ky). In mouse studies, they found that macrophage PI3Ky signaling promotes immune suppression by inhibiting activation of anti-tumor T cells. Blocking PI3Ky activated the immune response and significantly suppressed growth of implanted tumors in animal models. It also boosted sensitivity of some tumors to existing anti-cancer drugs and synergized with existing immune therapy to eradicate tumors. Varner and her colleagues at the Moores Cancer Center also identified a molecular signature of immune suppression and response in mice and cancer patients that may be used to track the effectiveness of immunotherapy.
“Recently developed cancer immunotherapeutics, including T cell checkpoint inhibitors and vaccines, have shown encouraging results in stimulating the body’s own adaptive immune response,” said co-author Ezra Cohen, MD, who heads the cancer immunotherapy program at Moores Cancer Center. “But they are effective only on a subset of patients, probably because they do not alter the profoundly immunosuppressive microenvironment created by tumor-associated macrophages. Our work offers a strategy to maximize patient responses to immune therapy and to eradicate tumors. ”
The Nature paper builds upon other work by Varner and colleagues. In a paper first published online in May in Cancer Discovery, Varner’s team reported that blocking PI3Ky in tumor-associated macrophages stimulated the immune response and inhibited tumor cell invasion, metastasis and fibrotic scarring caused by pancreatic ductal adenocarcinoma (PDAC) in animal models.
In humans, PDAC is the most common malignancy of the pancreas It’s aggressive and difficult to treat. Though only the 12th most common type of cancer in the United States, pancreatic cancer is the fourth most common cause of cancer-related death.
“PDAC has one of the worst 5-year survival rates of all solid tumors, so new treatment strategies are urgently needed,” said Megan M. Kaneda, PhD, an assistant project scientist in Varner’s lab and collaborator on all of the papers.
In a December 2015 paper published online in Cancer Discovery, Varner and colleagues described animal studies that revealed how disrupting cross-talk between B cells (another type of immune cell) and tumor-associated macrophages inhibited PDAC growth and improved responsiveness to standard-of-care chemotherapy.
Specifically, that research team, which included scientists in San Francisco, Oregon and Switzerland, reported that inhibiting Bruton tyrosine kinase, an enzyme that plays a crucial role in B cell and macrophage functions, restored T cell-dependent anti-tumor immune response. In other words, it reactivated the natural, adaptive immune response in tested mice.
The Latest on: Immune Suppression
via Google News
The Latest on: Immune Suppression
- Researchers pinpoint tumor-related protein, slow progression of cancers on April 17, 2019 at 10:02 am
Locking a biochemical gate that admits fuel into immune-suppressing cells could slow tumor progression and assist the treatment of multiple cancers, says new research from the Wistar Institute ... […]
- Immunotherapy Drugs Market is Anticipated to Cross US$ 289.52 Billion by 2024 on April 17, 2019 at 7:00 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- New York, April 17, 2019: Immunotherapy refers to treatments that stimulate, beautify or suppress the body’s personal immune system. Cancer segment is ... […]
- Explainer: what is Candida Auris and who is at risk? on April 16, 2019 at 11:41 pm
Risk factors include suppression of the immune system (such as via medication after organ transplants to prevent organ rejection), recent surgery, diabetes, and the presence of an in-dwelling ... […]
- Innate immune sensor responding to gut microbes can suppress liver cancer on April 16, 2019 at 11:33 pm
UT Southwestern researchers have found that a protein in the body's innate immune system that responds to gut microbes can suppress the most common type of liver cancer. The study, published today in ... […]
- The one Supreme Court case most likely to reveal Chief Justice Roberts’ soul on April 16, 2019 at 10:08 am
As a man, Roberts appears immune to sympathy for victims of voting ... Act plaintiffs would be able to prevail against voter suppression. As chief justice, Roberts voted to gut a key provision ... […]
- New role for innate immune sensor: Suppressing liver cancer on April 16, 2019 at 9:23 am
UT Southwestern researchers have found that a protein in the body's innate immune system that responds to gut microbes can suppress the most common type of liver cancer. NLRP12 is a member of the ... […]
- Independent Research Article on Kevetrin Submitted for Publication in a Leading Oncology Journal on April 16, 2019 at 6:31 am
After decades of efforts to fight cancer, both pharmaceutical industry and academic researchers have realized that single target approaches to tumor suppression are largely ... that leverage the ... […]
- Identification of lymph node cells that may play important roles in immune tolerance on April 10, 2019 at 7:13 am
Immune tolerance failure leads to autoimmune diseases. It is considered that peripheral T cell tolerance in lymph nodes consists of suppression by regulatory T cells, elimination of auto-reactive T ... […]
- Widely-Used Food Additive E319 Impairs Immune Responses to Influenza Infection on April 8, 2019 at 9:34 am
“Right now, our leading hypothesis is that tBHQ causes these effects by upregulating some proteins which are known to suppress the immune system,” Freeborn said. “Expression of these proteins, CTLA-4 ... […]
via Bing News